Company intelligence / Profile preview

OraLiva

New York City, New York, United States

Ownership: Private
Development stage: Other

Overview

OraLiva’s brush-biopsy and AI-powered cytology platform demonstrated >95% accuracy and was validated in a landmark NIH study (Phase II SBIR grant); delivers rapid, chairside results for early oral cancer detection, markedly outperforming traditional oral cancer screening approaches

Therapeutic areas: Oncology
Modalities: DeviceAI-powered cytology
Industry: Pathology

Partnerships

NYU College of DentistryAmerican Dental AssociationDelta Dental of MichiganCareQuest Innovation Partners

Beyond the preview

Go deeper on OraLiva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OraLiva.

Explore the full profile